Imprimis Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, IMMY, Imprimis Pharmaceuticals Inc, priceseries

Imprimis Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
4.67
Close
4.50
High
4.75
Low
4.50
Previous Close
4.66
Daily Price Gain
-0.16
YTD High
60.00
YTD High Date
Jan 28, 2010
YTD Low
0.50
YTD Low Date
Mar 19, 2012
YTD Price Change
-53.50
YTD Gain
-92.24%
52 Week High
60.00
52 Week High Date
Jan 28, 2010
52 Week Low
0.50
52 Week Low Date
Mar 19, 2012
52 Week Price Change
-53.50
52 Week Gain
-92.24%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 21. 2016
2.01
Jan 24. 2017
2.63
21 Trading Days
30.87%
Link
LONG
Feb 13. 2017
2.35
Feb 22. 2017
2.50
6 Trading Days
6.39%
Link
LONG
Mar 22. 2017
2.48
Apr 6. 2017
3.51
11 Trading Days
41.44%
Link
LONG
Apr 4. 2018
1.88
May 7. 2018
2.25
23 Trading Days
19.77%
Link
LONG
Aug 6. 2018
2.46
Aug 27. 2018
2.96
15 Trading Days
20.24%
Link
LONG
Oct 12. 2018
2.95
Nov 13. 2018
4.12
22 Trading Days
39.73%
Link
LONG
Dec 7. 2018
4.94
Dec 17. 2018
5.27
6 Trading Days
6.76%
Link
LONG
Dec 28. 2018
5.19
Jan 2. 2019
5.46
2 Trading Days
5.20%
Link
LONG
Jan 4. 2019
5.39
Jan 16. 2019
5.66
8 Trading Days
5.06%
Link
Company Information
Stock Symbol
IMMY
Exchange
NasdaqCM
Company URL
http://www.imprimispharma.com
Company Phone
858-704-4042
CEO
Mark L. Baum
Headquarters
California
Business Address
12264 EL CAMINO REAL, SUITE 350, SAN DIEGO, CA 92130
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001360214
About

Imprimis Pharmaceuticals, Inc. engages in the development, production, and dispensing of innovative proprietary compounded pharmaceuticals. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in San Diego, CA.

Description

Imprimis Pharmaceuticals, Inc. engages in the development, production, and sale of medications to physicians and patients in the United States. Its ophthalmology program consists of Dropless Therapy injectable and LessDrops topical formulations. The company also offers a conscious sedation medication, the IV Free MKO Melt, an alternative to intravenous sedation. It focuses on providing ophthalmology programs and medications for glaucoma, wet age-related macular degeneration, diabetic macular edema, and chronic dry eye disease. The company's medicine business includes medications used in several therapeutic areas, including oncology, autoimmunity, chronic infectious diseases, and endocrine and metabolic diseases; and urology business comprises a series of injectable erectile dysfunction formulations for patients that are refractory to or are otherwise unable to take phosphodiesterase type 5 inhibitors, such as sildenafil, tadalafil, and vardenafil. In addition, it develops PPS-DR (pentosan polysulfate sodium delayed-release) formulations as alternatives to Elmiron for patients diagnosed with interstitial cystitis; and develops and sells therapeutic alternatives to Daraprim, Thiola, and Calcium Disodium Versenate. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading